tion
type
ii
ifn
suggest
combin
may
potenti
treatment
sarscov
infect
mate
experiment
infect
sar
actual
therapeut
efficaci
postexposur
treatment
pegyl
yet
establish
regard
antivir
activ
ifn
previous
report
simultan
treatment
variou
concentr
iuml
act
synergist
sarscov
replic
vero
cell
similar
synergist
antivir
activ
sarscov
also
demonstr
other
differ
experiment
condit
name
use
higher
dose
combin
howev
recent
paraga
et
al
report
combin
consensu
exhibit
synergist
antivir
activ
sarscov
import
issu
support
search
effect
antisarscov
treatment
previou
studi
extend
evalu
vitro
antivir
activ
alon
combin
sarscov
infect
specif
goal
determin
whether
combin
ifn
would
produc
enhanc
antivir
effect
could
indirectli
suggest
potenti
combin
ifn
therapi
strategi
treatment
sarscov
effect
combin
ifn
sarscov
analys
yield
reduct
assay
specif
african
green
monkey
kidney
epitheli
cell
vero
cell
seed
plate
cell
per
well
cultur
overnight
triplic
cell
cultur
treat
concentr
iuml
recombin
specif
activ
miumg
rebif
aresserono
basel
switzerland
natur
leukocyt
ifn
specif
activ
miumg
alfaferon
alfawasserman
bologna
itali
either
alon
combin
specif
activ
miumg
imukin
boehring
ingelheim
reggellofirenz
itali
h
infect
sarscov
multipl
infect
tcid
cell
tissu
cultur
infecti
dose
infect
sarscov
strain
allow
develop
h
depend
time
requir
specif
cytopath
effect
becom
clearli
visibl
optic
microscopi
cultur
supernat
collect
titrat
sarscov
perform
vero
cell
determin
tcid
use
method
reed
muench
expect
tabl
exogen
ad
exhibit
minor
inhibitori
effect
yield
infecti
sarscov
vero
cell
use
alon
valu
inhibitori
concentr
ic
rang
ium
iuml
howev
differ
concentr
use
combin
differ
concentr
inhibit
viru
yield
pronounc
inde
ic
valu
decreas
markedli
differ
ifn
use
combin
specif
ic
valu
sarscov
yield
combin
log
fold
lower
compar
ic
valu
treatment
alon
ic
valu
show
log
fold
decreas
use
combin
rel
valu
record
alon
interestingli
synergist
antivir
effect
combin
also
observ
low
concentr
iuml
expect
result
tabl
also
confirm
previou
find
synergist
effect
extend
experi
statist
analysi
clearli
show
concentr
requir
inhibit
viral
yield
product
significantli
decreas
use
combin
compar
singl
treatment
p
detail
analysi
natur
antivir
interact
type
ii
ifn
replic
sarscov
undertaken
use
isobologram
combin
index
ci
method
chou
talalay
gener
equat
classic
isobologram
given
follow
isobologram
construct
viral
yield
reduct
valu
rang
experiment
combin
therapi
data
point
plot
well
expect
addit
line
viral
yield
reduct
valu
type
ifn
plu
combin
indic
strong
synerg
across
broad
rang
dose
data
shown
ci
valu
interact
type
ifn
entir
rang
viral
yield
reduct
valu
test
indic
strong
synerg
fig
mechan
type
ii
ifn
synergis
inhibit
sarscov
yet
unclear
previou
studi
suggest
mxa
typeiinduc
protein
critic
factor
mediat
inhibit
sarscov
despit
highlevel
induct
well
mixtur
henc
order
discov
possibl
mechan
respons
observ
synerg
type
ii
ifn
examin
express
two
wellknown
ifninduc
protein
oligoadenyl
synthetas
also
known
mrna
copi
content
gene
measur
untreat
versu
ifntreat
vero
cell
realtim
exonucleas
revers
transcript
polymeras
chain
reaction
taqman
assay
use
abi
sequenc
detector
appli
biosi
tem
monza
itali
briefli
total
cellular
rna
extract
vero
cell
use
phenol
guanidin
isothiocyan
reagent
trizol
gibco
brl
grand
island
ny
usa
follow
manufactur
instruct
transcrib
use
highcapac
cdna
archiv
kit
appli
biosystem
next
follow
primer
pair
probe
ad
univers
pcr
master
mix
appli
biosystem
n
respect
final
volum
l
oligoadenyl
synthetas
forward
revers
probe
fam
rhodamin
tamra
forward
revers
probe
tamra
coamplif
hypoxanthin
phosphoribosyltransferas
mrna
housekeep
gene
taqman
endogen
control
appli
biosystem
use
normalis
amount
total
rna
present
consid
differ
ifn
prepar
differ
specif
activ
iumg
protein
vero
cell
expos
ngml
either
iuml
iuml
iuml
type
ifn
ngml
h
result
show
ifn
test
induc
detect
amount
oligoadenyl
synthetas
mrna
fig
interestingli
oligoadenyl
synthetas
transcript
level
increas
significantli
stimul
vero
cell
compar
transcript
level
obtain
stimul
either
ifn
alon
tempt
specul
increas
express
oligoadenyl
synthetas
combin
type
ifn
use
could
due
synergist
interact
type
ii
ifn
induct
ifnstimul
gene
factor
type
receptor
possibl
address
perform
focus
studi
present
definit
conclus
drawn
mechan
underli
strong
synerg
record
summari
data
extend
accomplish
previou
result
demonstr
combin
produc
significantli
enhanc
antivir
activ
sarscov
infect
compar
individu
ifn
synerg
parallel
increas
express
oligoadenyl
synthetas
mrna
emphasis
vitro
studi
thu
far
perform
vero
cell
unabl
obtain
viral
progeni
human
cell
line
includ
caco
employ
other
thu
unabl
assess
activ
variou
ifn
proper
human
system
firm
conclus
extrapol
drawn
ifn
inhibitori
concentr
valu
obtain
regard
potenti
therapeut
concentr
ifn
might
expect
requir
clinic
situat
nevertheless
find
suggest
investig
may
warrant
determin
role
plu
therapeut
strategi
treatment
sarscov
infect
work
support
part
grant
ga
univers
la
sapienza
fondi
ateneo
quota
data
normalis
hypoxanthin
phosphoribosyltransferas
mrna
calcul
use
arithmet
formula
ct
accord
supplier
guidelin
p
compar
fold
chang
oligoadenyl
synthetas
exposur
vero
cell
separ
use
student
test
